| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Coastlands Capital Partners LP | 9.3% | $3,632,511 | 2,815,900 | Coastlands Capital LP | 28 May 2025 | |||
| Adjuvant Global Health Technology Fund, L.P. | 7.9% | $3,061,815 | 2,373,500 | Adjuvant Capital GP, L.P. | 31 Dec 2024 | |||
| Easom Eric | 6.2% | $2,442,140 | 1,893,132 | Eric Easom | 31 Dec 2024 | |||
| Almitas Capital LLC | 5.2% | $1,813,970 | 1,428,323 | Almitas Capital LLC | 30 Sep 2025 | |||
| Brii Biosciences Ltd | 3.1% | $1,196,089 | 927,201 | Brii Biosciences Limited | 31 Dec 2024 | |||
| BML Investment Partners, L.P. | 1.4% | -84.5% | $551,387 | -$3,599,088 | 427,432 | -86.7% | BML Investment Partners, L.P. | 17 Jun 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 8,276,317 | $10,511,010 | +$7,414 | $1.27 | 35 |
| 2025 Q2 | 8,284,557 | $8,781,263 | -$8,600,258 | $1.06 | 36 |
| 2025 Q1 | 14,340,830 | $19,503,615 | -$264,699 | $1.36 | 37 |
| 2024 Q4 | 14,528,930 | $20,050,012 | +$893,482 | $1.38 | 37 |
| 2024 Q3 | 13,513,224 | $14,458,906 | -$16,315,888 | $1.07 | 31 |
| 2024 Q2 | 19,415,909 | $41,730,123 | -$1,462,207 | $2.15 | 45 |
| 2024 Q1 | 18,733,564 | $60,875,021 | -$18,042,573 | $3.25 | 54 |
| 2023 Q4 | 20,391,503 | $417,920,110 | +$9,592,150 | $20.49 | 51 |
| 2023 Q3 | 19,931,490 | $320,311,244 | +$132,978,201 | $16.08 | 37 |
| 2023 Q2 | 11,741,328 | $99,891,167 | +$18,097,549 | $8.5 | 30 |
| 2023 Q1 | 9,600,229 | $94,752,948 | -$1,565,644 | $9.87 | 37 |
| 2022 Q4 | 9,762,608 | $93,037,767 | -$3,679,262 | $9.53 | 35 |
| 2022 Q3 | 9,496,676 | $165,051,000 | +$1,938,968 | $17.38 | 35 |
| 2022 Q2 | 9,386,370 | $72,410,000 | +$2,199,519 | $7.75 | 32 |
| 2022 Q1 | 8,952,537 | $134,111,000 | +$134,111,000 | $15.07 | 18 |